The global cetrotide market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Cetrotide is also known as Cetrorelix that belongs to the class of medications called GnRH antagonists. The major factor expected to drive the market is that it blocks the effects of gonadotropin-releasing hormone GnRH. In addition, GnRH controls the secretion of another hormone, called luteinizing hormone (LH), a hormone that starts ovulation (release of an egg) during the menstrual cycle. Furthermore, Cetrotide also allows the release of an egg to be controlled so it is released at the best time for pregnancy to occur, these are the factors that drive market growth. Furthermore, the market is growing as Cetrotide medication starts suppression hormone production in the pituitary gland almost as soon as it is administered in compression to any other fertility medication.
Cetrotide is also known as Cetrorelix is a subcutaneous injection that is prescribed to women undergoing controlled stimulation treatment. The medication supports to prevent a rise in luteinizing hormone (LH) levels, which can trigger early ovulation. It regulates the functioning of the pituitary gland. Further this gland is responsible for the production of hormones that stimulate the growth of an egg, its development, and release once it is mature.
Some major players in the market include Merck kGaA, and Ferring Pharmaceuticals BV, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in September 2021, Ferring International Center S.A. collaborate with Hybio Pharmaceutical Co. Ltd. where the Marketing Authorization of Cetrotide (cetrorelix acetate for injection) in Mainland China will be transferred to Ferring Pharmaceuticals; and Hybio Pharmaceutical will act as the contract manufacturing organization of Ferring Pharmaceuticals.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Cetrotide Market at: https://orionmarketreports.com/request-sample/?id=98205&submit=Request+Sample%0D%0A
Market Coverage
- The market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By Distribution Channel
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Merck kGaA, and Ferring Pharmaceuticals BV, among others.
A full report Cetrotide Market of is available at: https://orionmarketreports.com/cetrotide-market/98205/
Global Cetrotide Market Report by Segment
By Type
- Vial with Powder
- Pre-filled Syringe
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
